Get Flat 15% Discount on ED Drugs for orders value $70 or more
  • Danielle Jolla, United States says, "I love your online pharmacy Because of your quick shipping and reasonable prices."
  • Jill Barrella, United States says, "Seemed easy to purchase, reasonable prices. Good customer service when I used it."
  • Brian Pavey, United States says, "I am very satisfied with IDM and plan on making more purchases in the future. IDMs prices are low which makes it very compelling to use over conventional pharmacies with high copays and more restrictions continually implemented."
  • Eric Gonzales, United States says, "The website is very user friendly, there is a lot of variety and checking out was easy."
  • Albert Martinez, United States says, "Very organized and efficient concerning delivery and products are great. Very satisfied, impressed with delivery and product."
  • Natalie Wallace, United States says, "I absolutely love getting my medications at a great price and I always get that here. And I recommend this site to my family and friends."
  • Ask our pharmacist, if you have any questions related to your medications
    Click to find International Shipping charges at our pharmacy.
    Shop & Earn @ InternationalDrugMart
    Easy and secure shopping @
    Get your instant Coupon now!
    Price challenge
    You can find the latest happening of our pharmacy Visit to discuss on various diseases and conditions
    Follow us on Twitter
    You are here: Home > Pharmacy News | Health Articles/Tips > Cipla > January 01, 2008

      Cipla maintains No.1 position in Indian mkt


      Tops pharma rankings with 5.42% market share, a head of Ranbaxy and GSK.

      Cipla Laboratories continues to be the largest pharmaceutical company in the domestic market.

      Cipla has topped the ORG-IMS rankings for the month of November with a market share of 5.42 per cent and sales of Rs 146.32 crore, edging out Ranbaxy which stood at second position with 5.09 per cent market share and Rs 137.49 crore sales.

      In October, Cipla topped with Rs 152.04 crore sales and a market share of 5.23 per cent, ahead of Ranbaxy, which garnered Rs 148.40 crore sales and 5.11 per cent market share, said sources.

      Cipla overtook Ranbaxy and GlaxoSmithKline India (GSK) to become the largest pharmaceutical company in the domestic market for the first time in May 2007.

      While GSK has maintained its number three position in November, Zydus Cadila (fourth), Alkem Laboratories (fifth) and Sun Pharma (sixth) have moved one rank up from October.

      Nicholas Piramal, which faced raw material shortages for its largest selling codiene based formulations, like Phensydyl, in recent months, slipped three positions to number seven in November.

      ORG-IMS, the largest market intelligence company in India focusing on the healthcare sector, tracks sales of Indian pharmas on a monthly basis, through over 3,000 stockists and 6,000 doctors.

      “Indian companies are increasing their share in the domestic market mainly due to increased number of high value new introductions, though the number of new introductions have reduced recently,” Shailesh Gadre, managing director, ORG-IMS, said in an interview last week.

      Ranbaxy’s growth has been largely driven by new introductions such as Volix, an anti-Diabetes drug launched in January, Oframax-Forte and anti-asthmatic drug Synasma, which it in-licensed from Eurodrug Laboratories.

      Ranbaxy’s antibiotic Mox (amoxyllin), which was not among the top ten brands a year ago, has grown to become the fourth largest brand in the domestic market with monthly sales at Rs 9.8 crore in November, sources said.

      Cipla’s growth was powered by positive growth in their existing portfolio, especially its respiratory products.

      However, GSK has lost market share mainly in its main portfolios such as anti- infectives, dermatologicals and pain management drugs which grew slower than the market for these products, ORG-IMS said.

      ORG-IMS named Alkem Laboratories as the only company among the top ten for which both older products (10 per cent) and new introductions (12 per cent) have contributed significantly to value growth.

      “Our growth in the domestic market is mainly due to the growth of our anti-infective Taxim and other brands such as Taximo, Clavem, A to Z and Gemcal,” explained Vinod Dua, head, domestic business of Alkem Laboratories.

      Alkem’s Taxim is now the third largest brand in the domestic market with sales of Rs 10.3 crore, behind Pfizer’s Cough syrup Corex (Rs 15.2 crore) and Novartis India’s pain killer Voveron (Rs 11.6 crore).

      January 01, 2008


      Share this Article!

    Back to top^